QCI Asset Management Inc. NY grew its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 41,331 shares of the biopharmaceutical company’s stock after buying an additional 595 shares during the quarter. Regeneron Pharmaceuticals makes up about 1.6% of QCI Asset Management Inc. NY’s investment portfolio, making the stock its 28th biggest position. QCI Asset Management Inc. NY’s holdings in Regeneron Pharmaceuticals were worth $16,699,000 at the end of the most recent reporting period.
A number of other institutional investors have also recently modified their holdings of REGN. Wrapmanager Inc. lifted its position in shares of Regeneron Pharmaceuticals by 9.9% during the second quarter. Wrapmanager Inc. now owns 1,440 shares of the biopharmaceutical company’s stock worth $497,000 after purchasing an additional 130 shares in the last quarter. Raymond James Financial Services Advisors Inc. lifted its position in shares of Regeneron Pharmaceuticals by 4.7% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 3,144 shares of the biopharmaceutical company’s stock worth $1,085,000 after purchasing an additional 141 shares in the last quarter. Traynor Capital Management Inc. lifted its position in shares of Regeneron Pharmaceuticals by 9.8% during the second quarter. Traynor Capital Management Inc. now owns 1,631 shares of the biopharmaceutical company’s stock worth $572,000 after purchasing an additional 145 shares in the last quarter. Atria Investments LLC lifted its position in shares of Regeneron Pharmaceuticals by 10.9% during the second quarter. Atria Investments LLC now owns 1,497 shares of the biopharmaceutical company’s stock worth $516,000 after purchasing an additional 147 shares in the last quarter. Finally, MUFG Securities EMEA plc lifted its position in shares of Regeneron Pharmaceuticals by 1.7% during the second quarter. MUFG Securities EMEA plc now owns 9,031 shares of the biopharmaceutical company’s stock worth $3,116,000 after purchasing an additional 152 shares in the last quarter. 66.06% of the stock is currently owned by hedge funds and other institutional investors.
REGN opened at $356.66 on Friday. The company has a current ratio of 4.04, a quick ratio of 2.92 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $39.36 billion, a price-to-earnings ratio of 19.97, a PEG ratio of 1.22 and a beta of 1.34. Regeneron Pharmaceuticals Inc has a twelve month low of $281.89 and a twelve month high of $416.49.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.94 by $0.93. The company had revenue of $1.66 billion for the quarter, compared to analyst estimates of $1.64 billion. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The business’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period last year, the business posted $3.99 earnings per share. Research analysts predict that Regeneron Pharmaceuticals Inc will post 19.31 earnings per share for the current year.
A number of equities analysts have recently issued reports on the stock. TheStreet upgraded shares of Regeneron Pharmaceuticals from a “c” rating to a “b-” rating in a research report on Wednesday, July 25th. JPMorgan Chase & Co. set a $405.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday. Robert W. Baird lowered shares of Regeneron Pharmaceuticals from an “outperform” rating to a “neutral” rating in a report on Friday, August 3rd. Cowen restated a “hold” rating and issued a $385.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday. Finally, BidaskClub upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, October 19th. Two analysts have rated the stock with a sell rating, seventeen have issued a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $410.95.
In other Regeneron Pharmaceuticals news, Director Michael S. Brown sold 2,000 shares of the stock in a transaction on Thursday, September 27th. The shares were sold at an average price of $392.26, for a total value of $784,520.00. Following the sale, the director now directly owns 2,000 shares in the company, valued at $784,520. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Michael S. Brown sold 1,500 shares of the stock in a transaction on Wednesday, August 22nd. The stock was sold at an average price of $380.49, for a total transaction of $570,735.00. Following the completion of the sale, the director now owns 1,500 shares in the company, valued at $570,735. The disclosure for this sale can be found here. Over the last quarter, insiders sold 110,052 shares of company stock worth $44,651,762. Company insiders own 12.42% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Regeneron Pharmaceuticals Inc (REGN) Shares Bought by QCI Asset Management Inc. NY” was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2018/11/10/regeneron-pharmaceuticals-inc-regn-shares-bought-by-qci-asset-management-inc-ny.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: NASDAQ
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.